KEVAN ENGLİSH, CHRİSTİNE UWİBAMBE
The Ulutas Medical Journal - 2025;11(2):22-24
Obesity is a well-known risk factor for heart failure with preserved ejection fraction (HFpEF). Through recent clinical trials, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been shown to decrease mortality and improve symptoms in patients with obesity and HFpEF. Based on the new existing data, we suggest a change in clinical practice for physicians globally. Evidence now supports the initiation of GLP1/GIP agonists in patients with obesity and HFpEF. This short communication reviews some of the most recent data on GLP-1/GIP agonists that support their clinical indications for patients with obesity and heart failure.
